≡ Risteys
R9

Documentation Changelog GitHub Contact & Feedback

Carcinoma in situ, bladder (controls excluding all cancers)

PheWeb

CD2_INSITU_BLADDER_EXALLC

No definition available.

Endpoint definition

↥
FinnGen phenotype data

individuals

diagram downward connector

Apply sex-specific rule None

diagram downward connector
diagram bullet

Check conditions

not C3_BLADDER

diagram downward connector
diagram bullet

Check pre-conditions, main-only, mode, registry filters

Hospital Discharge: ICD-10 D09.0&
Hospital discharge: ICD-9 2337
Cause of death: ICD-10 D09.0&
Cause of death: ICD-9 2337
Cancer registry: Topography ICD-O-3 C67
Cancer registry: Morphology ICD-O-3 ANY
Cancer registry: Behaviour codes 2

3 out of 7 registries used, show all original rules.

-

diagram downward connector

Check minimum number of events None

-

diagram downward connector

Include endpoints None

-

diagram downward connector
diagram bullet diagram downward connector

Remove individuals based on genotype QC

654

diagram downward connector
CD2_INSITU_BLADDER_EXALLC

Control definitions

Control exclude C3_CANCER, C3_CANCER_WIDE

Extra metadata

Level in the ICD hierarchy 3
First used in FinnGen datafreeze DF9
Parent code in ICD-10 D09

Summary Statistics

↥

Key figures

All Female Male
Number of individuals 654 116 538
Unadjusted prevalence (%) 0.17 0.06 0.32
Mean age at first event (years) 70.51 67.71 71.11

Mortality

Follow-up Absolute risk HR [95% CI] p N
1998–2019 0.03 2.14 [1.10, 4.17] 2.5e-2 53
15 years 0.00 0.74 [0.35, 1.57] 4.3e-1 18
5 years 0.00 2.00 [0.93, 4.30] 7.7e-2 29
1 year - - - -

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

↥

Index endpoint: CD2_INSITU_BLADDER_EXALLC – Carcinoma in situ, bladder (controls excluding all cancers)
GWS hits:

Survival analyses between endpoints

↥

Plot

before Carcinoma in situ, bladder (controls excluding all cancers)
after Carcinoma in situ, bladder (controls excluding all cancers)

loading spinner Loading survival analyses plot

Drugs most likely to be purchased after Carcinoma in situ, bladder (controls excluding all cancers)

↥

Endpoint not on priority list, no data to show.